ramucirumab,pembrolizumab
eli lilly,merck
['pembro', 'ramucirumab', 'lung-map', 'nsclc', 'lung', 's1800a', 'sclc']
osl from phase ii rct of ramucirumab + pembrolizumab versus standard of care for advanced nsclc previously treated with immunotherapy: lung-map nonmatched substudy s1800a. #ncorp #asco22 
Medical oncologist, retired. Interests are community-based cancer research, rural cancer care, solid tumor biology & treatment.